



NDA 21-344/S-004

AstraZeneca Pharmaceuticals LP
Attention: Debra N. Shiozawa, Ph.D.
Regulatory Affairs Associate Director
1800 Concord Pike
P.O. Box 8355
Wilmington, DE 19803-8355

Dear Dr. Shiozawa:

Please refer to your supplemental new drug application dated February 1, 2005, received February 2, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for FASLODEX[®] (fulvestrant) Injection.

This "Changes Being Effected" supplemental new drug application provides for updated survival language in the **CLINICAL PHARMACOLOGY-Clinical Studies** section. Also, the **ADVERSE REACTIONS** section has been updated to include hypersensitivity reactions.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the attached labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-344/S-004.**" Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 21-344/S-004

Page 2

If you have any questions, call Amy Baird, Consumer Safety Officer, at (301) 594-5779.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D.
Acting Director
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Robert Justice
8/2/05 05:47:19 PM